Drug Trial Radar · NCT04948333
Asciminib Treatment Optimization in ≥ 3rd Line CML-CP
Last checked: Nov 20, 2026Latest source record: Mar 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
199
Actual
Start
Oct 13, 2021
Primary completion
Mar 12, 2024
Study completion Feb 25, 2026
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jul 1, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to optimize the treatment of asciminib in patients with chronic myelogenous leukemia in chronic phase (CML-CP) previously treated with 2 or more Tyrosine Kinase Inhibitors (TKIs).
Conditions
- Chronic Myelogenous Leukemia
Interventions
ABL001 40mg BIDDrug
One tablet of 40 mg will be taken orally twice a day (BID)
ABL001 80mg QDDrug
Two tablets of 40 mg will be taken orally once a day (QD)
ABL001 200mg QDDrug
Five tablets of 40 mg will be taken orally once a day (QD)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Major Molecular Response (MMR) Rate at Week 48 for All Patients With no Evidence of MMR at BaselineTime frame: Week 48
Locations
48 sites in 16 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
Graz, Austria
Novartis Investigative Site
Linz, Austria
Novartis Investigative Site
Vienna, Austria
Novartis Investigative Site
São Paulo, Brazil
Novartis Investigative Site
Rio de Janeiro, Rio de Janeiro, Brazil
Novartis Investigative Site
Vancouver, British Columbia, Canada
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Bordeaux, France
Novartis Investigative Site
Lyon, France
Novartis Investigative Site
Montpellier, France
Novartis Investigative Site
Nantes, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Kiel, Germany
Novartis Investigative Site
München, Germany
Novartis Investigative Site
Mannheim, Baden-Wurttemberg, Germany
Novartis Investigative Site
Frankfurt am Main, Hesse, Germany
Novartis Investigative Site
Jena, Thuringia, Germany
Novartis Investigative Site
Athens, Greece
Novartis Investigative Site
Thessaloniki, Greece
Novartis Investigative Site
Monza, MB, Italy
Novartis Investigative Site
Roma, RM, Italy
Novartis Investigative Site
Verona, VR, Italy
Novartis Investigative Site
Johor Bahru, Malaysia
Novartis Investigative Site
Kuala Selangor, Malaysia
Novartis Investigative Site
George Town, Pulau Pinang, Malaysia
Novartis Investigative Site
Kota Kinabalu, Sabah, Malaysia
Novartis Investigative Site
Khoudh, Oman
Novartis Investigative Site
Katowice, Poland
Novartis Investigative Site
Warsaw, Poland
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Taegu, South Korea
Novartis Investigative Site
Seoul, Korea, South Korea
Novartis Investigative Site
Barcelona, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Santiago Compostela, A Coruna, Spain
Showing 40 of 48 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.